Announcement of the Convening of the General Meeting in Munich/Germany on 19/05/2011 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
(Thomson Reuters ONE) -
MorphoSys AG /
Announcement of the Convening of the General Meeting in Munich/Germany on
19/05/2011 according to article 121 AktG (German Stock Companies Act) with the
objective of Europe-wide distribution
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG
Martinsried/Planegg
Securities' code numbers: 663200 and A1H303
ISIN:DE0006632003 and DE000A1H3036
Invitation to the Annual Shareholders' Meeting 2011
We hereby invite the shareholders of our Company to the Annual Shareholders'
Meeting which is taking place on Thursday, May 19, 2011 at 10.00 a.m., in the
Conference Centre Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636
Munich.
Agenda
1. Presentation of the confirmed annual financial statements as of December
31, 2010, the management report together with the consolidated financial
statements, the consolidated management report and the report of the
Supervisory Board for the business year 2010 and the statement of the Board
of Management to the items pursuant to § § 289 para. 4, 315 para. 4 HGB
2. Formal approval on behalf of the Board of Management
3. Formal approval on behalf of the Supervisory Board
4. Appointment of the auditors for the business year 2011
5. New Election to the Supervisory Board
6. Resolution on the Approval of the Remuneration Scheme of Members of the
Board of Management
7. Resolution on the Authorization to purchase and use Treasury Stock and on
the Exclusion of Subscription Rights
8. Creation of a new Conditional Capital 2011-I, authorization on behalf of the
Board of Management to issue option and/or convertible bonds, exclusion of
Subscription Rights; amendment of the Articles
9. Compensation of the Supervisory Board by Secondary Payments of the Company,
Amendment of the Articles
Please find the full text of the announcement here: www.morphosys.com/agm
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1503984]
Unternehmensinformation / Kurzprofil:
Datum: 06.04.2011 - 15:50 Uhr
Sprache: Deutsch
News-ID 53227
Anzahl Zeichen: 5355
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 308 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Announcement of the Convening of the General Meeting in Munich/Germany on 19/05/2011 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
